PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.47%
Revenue growth at 50-75% of MRVL's 4.84%. Martin Whitman would worry about competitiveness or product relevance.
1.64%
Gross profit growth under 50% of MRVL's 4.67%. Michael Burry would be concerned about a severe competitive disadvantage.
3.82%
EBIT growth below 50% of MRVL's 79.51%. Michael Burry would suspect deeper competitive or cost structure issues.
1.96%
Operating income growth under 50% of MRVL's 79.51%. Michael Burry would be concerned about deeper cost or sales issues.
0.82%
Net income growth under 50% of MRVL's 102.60%. Michael Burry would suspect the firm is falling well behind a key competitor.
0.53%
EPS growth under 50% of MRVL's 102.50%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
1.08%
Diluted EPS growth under 50% of MRVL's 102.50%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.11%
Share reduction more than 1.5x MRVL's 2.70%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
-0.11%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
20.60%
OCF growth under 50% of MRVL's 70.17%. Michael Burry might suspect questionable revenue recognition or rising costs.
-126.40%
Negative FCF growth while MRVL is at 63.98%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
80.64%
10Y revenue/share CAGR above 1.5x MRVL's 22.84%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
21.37%
5Y revenue/share CAGR under 50% of MRVL's 47.63%. Michael Burry would suspect a significant competitive gap or product weakness.
41.12%
3Y revenue/share CAGR at 50-75% of MRVL's 72.96%. Martin Whitman would question if the firm lags behind competitor innovations.
152.14%
10Y OCF/share CAGR above 1.5x MRVL's 15.80%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-17.56%
Negative 5Y OCF/share CAGR while MRVL is at 92.70%. Joel Greenblatt would question the firm’s operational model or cost structure.
-17.95%
Negative 3Y OCF/share CAGR while MRVL stands at 239.31%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
216.94%
Positive 10Y CAGR while MRVL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
31.88%
Positive 5Y CAGR while MRVL is negative. John Neff might view this as a strong mid-term relative advantage.
25.88%
Below 50% of MRVL's 105.61%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
74.95%
10Y equity/share CAGR at 50-75% of MRVL's 113.69%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
61.29%
Below 50% of MRVL's 130.01%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
110.37%
3Y equity/share CAGR above 1.5x MRVL's 61.39%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
342.27%
10Y dividend/share CAGR above 1.5x MRVL's 0.70%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
99.75%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
37.90%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
4.21%
AR growth well above MRVL's 8.41%. Michael Burry fears inflated revenue or higher default risk in the near future.
13.41%
Inventory growth well above MRVL's 9.29%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.88%
Asset growth above 1.5x MRVL's 0.56%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.46%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
10.79%
Debt growth far above MRVL's 1.35%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
4.84%
R&D growth drastically higher vs. MRVL's 1.10%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-2.74%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.